Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DORZOLAMIDE FOR SYSTEM SUITABILITY CRS (5 MG)

DORZOLAMIDE FOR SYSTEM SUITABILITY CRS (5 MG)

130693-82-2

DISCOVER
FEXOFENADINE IMPURITY A CRS (5 MG)

FEXOFENADINE IMPURITY A CRS (5 MG)

NA

DISCOVER
FEXOFENADINE IMPURITY B CRS (0.01 MG)

FEXOFENADINE IMPURITY B CRS (0.01 MG)

NA

DISCOVER
FEXOFENADINE IMPURITY C CRS (5 MG)

FEXOFENADINE IMPURITY C CRS (5 MG)

NA

DISCOVER
METHENAMINE CRS (10 MG)

METHENAMINE CRS (10 MG)

100-97-0

DISCOVER
NONOXINOL 9 CRS (10 MG)

NONOXINOL 9 CRS (10 MG)

26027-38-3

DISCOVER
Fenoterol for peak identification

Fenoterol for peak identification

03/12/1944

DISCOVER
RIBOFLAVIN FOR PEAK IDENTIFICATION CRS (0.12 MG)

RIBOFLAVIN FOR PEAK IDENTIFICATION CRS (0.12 MG)

83-88-5

DISCOVER
CLOZAPINE FOR PEAK IDENTIFICATION CRS (0.41 MG)

CLOZAPINE FOR PEAK IDENTIFICATION CRS (0.41 MG)

5786-21-0

DISCOVER
TRIMIPRAMINE FOR PEAK IDENTIFICATION CRS (0.51 MG)

TRIMIPRAMINE FOR PEAK IDENTIFICATION CRS (0.51 MG)

521-78-8

DISCOVER
VINPOCETINE IMPURITY D CRS (15 MG)

VINPOCETINE IMPURITY D CRS (15 MG)

NA

DISCOVER
PHOLCODINE CRS - * NARC (10 MG)

PHOLCODINE CRS - * NARC (10 MG)

509-67-1

DISCOVER